Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Elham Aida FarshadiJiang ChangBharath SampadiMichail DoukasFreek Van 't LandFleur van der SijdeEveline E VietschJoris PothofBas Groot KoerkampCasper H J van EijckPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Resistance development in neoadjuvant FOLFIRINOX organoids, recapitulating their primary tumor resistance, suggests continuation of FOLFIRINOX therapy as an adjuvant treatment may not be advantageous for these patients. Gene-expression profiles of PDAC organoids identify targetable pathways involved in chemoresistance development upon neoadjuvant FOLFIRINOX treatment, thus opening up combination therapy possibilities.